Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for RCUS

Stock NameArcus Biosciences Inc
TickerRCUS(USD) NYSE
TYPECommon Stock
CountryUSA
ISINUS03969F1093

Show aggregate RCUS holdings

News associated with RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) Receives $21.14 Average Target Price from Analysts
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target […] - 2025-09-09 02:29:02
US Bancorp DE Buys 12,869 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
US Bancorp DE increased its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 186.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,756 shares of the company’s stock after acquiring an additional 12,869 shares during the period. US […] - 2025-08-17 05:14:59
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $21.14 Consensus Price Target from Brokerages
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price […] - 2025-08-15 02:10:59
Universal Beteiligungs und Servicegesellschaft mbH Makes New $138,000 Investment in Arcus Biosciences, Inc. (NYSE:RCUS)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 17,631 shares of the company’s stock, valued at approximately $138,000. A number of other […] - 2025-08-06 04:28:49
Y Intercept Hong Kong Ltd Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS)
Y Intercept Hong Kong Ltd acquired a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 31,414 shares of the company’s stock, valued at approximately $247,000. A number of […] - 2025-07-31 05:00:52
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Louisiana State Employees Retirement System
Louisiana State Employees Retirement System boosted its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,700 shares of the company’s stock after purchasing an additional 5,600 shares during the quarter. Louisiana State […] - 2025-07-22 07:17:17
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong […] - 2025-06-23 03:12:48
GAMMA Investing LLC Purchases 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
GAMMA Investing LLC lifted its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 1,399.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,571 shares of the company’s stock after purchasing an additional 15,466 shares during the period. GAMMA Investing LLC’s holdings in Arcus Biosciences were […] - 2025-06-16 04:26:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% in the fourth quarter, HoldingsChannel reports. The firm owned 62,014 shares of the company’s stock after selling 7,872 shares during the quarter. UBS AM a distinct business unit […] - 2025-06-11 04:36:52
ProShare Advisors LLC Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)
ProShare Advisors LLC lifted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 44.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 16,379 shares of the company’s stock after buying an additional 5,038 shares during the quarter. ProShare Advisors LLC’s holdings in Arcus Biosciences were worth $244,000 as of […] - 2025-06-01 05:46:50
Jane Street Group LLC Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS)
Jane Street Group LLC cut its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 6.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 202,500 shares of the company’s stock after selling 14,541 shares during the quarter. Jane Street Group LLC’s holdings in Arcus Biosciences were worth $3,015,000 at the […] - 2025-05-14 06:38:56
Voya Investment Management LLC Acquires 6,733 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Voya Investment Management LLC increased its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 37.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 24,674 shares of the company’s stock after acquiring an additional 6,733 shares during the period. Voya Investment Management LLC’s holdings in Arcus Biosciences were worth $367,000 at […] - 2025-05-11 05:44:50
Arcus Biosciences (NYSE:RCUS) Shares Gap Down Following Weak Earnings
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price gapped down prior to trading on Wednesday following a weaker than expected earnings announcement. The stock had previously closed at $8.12, but opened at $7.44. Arcus Biosciences shares last traded at $7.47, with a volume of 384,839 shares trading hands. The company reported ($1.14) earnings […] - 2025-05-09 02:40:50
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP raised its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,702,302 shares of the company’s stock after buying an additional 178,351 shares during the period. Dimensional Fund Advisors LP’s holdings in Arcus Biosciences were worth […] - 2025-05-07 05:26:54
MetLife Investment Management LLC Purchases 2,521 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
MetLife Investment Management LLC boosted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 8.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,525 shares of the company’s stock after purchasing an additional 2,521 shares during the period. MetLife […] - 2025-05-06 05:41:07
Invesco Ltd. Raises Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)
Invesco Ltd. boosted its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 203,987 shares of the company’s stock after buying an additional 35,905 shares during the quarter. Invesco Ltd.’s holdings in Arcus […] - 2025-04-28 04:54:53
Legal & General Group Plc Sells 1,837 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Legal & General Group Plc cut its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 1.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 149,207 shares of the company’s stock after selling 1,837 shares during the quarter. Legal & General Group Plc’s holdings in Arcus Biosciences were worth […] - 2025-04-25 05:10:47
KLP Kapitalforvaltning AS Makes New $207,000 Investment in Arcus Biosciences, Inc. (NYSE:RCUS)
KLP Kapitalforvaltning AS purchased a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 13,900 shares of the company’s stock, valued at approximately $207,000. Other institutional investors and hedge funds have also […] - 2025-04-08 05:44:58
Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $30.25
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has been assigned a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-03-20 04:52:43
AlphaQuest LLC Has $110,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS)
AlphaQuest LLC reduced its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,405 shares of the company’s stock after selling 2,026 shares during the quarter. AlphaQuest LLC’s holdings […] - 2025-03-19 06:10:45
Principal Financial Group Inc. Purchases 7,906 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Principal Financial Group Inc. increased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 3.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 263,517 shares of the company’s stock after buying an additional 7,906 shares during the quarter. Principal Financial Group Inc.’s holdings in Arcus Biosciences were worth $3,924,000 at the […] - 2025-03-05 06:22:48
Handelsbanken Fonder AB Purchases 2,500 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Handelsbanken Fonder AB grew its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,800 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Handelsbanken Fonder […] - 2025-03-03 06:59:09
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by New York State Teachers Retirement System
New York State Teachers Retirement System lowered its holdings in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 3.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 90,543 shares of the company’s stock after selling 3,708 shares during the quarter. New York State Teachers Retirement System’s holdings in Arcus Biosciences were worth $1,348,000 […] - 2025-02-24 06:25:09
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Average Target Price from Brokerages
Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong […] - 2025-02-21 04:48:43
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week Low on Analyst Downgrade
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price hit a new 52-week low during trading on Wednesday after Morgan Stanley lowered their price target on the stock from $36.00 to $25.00. Morgan Stanley currently has an overweight rating on the stock. Arcus Biosciences traded as low as $10.65 and last traded at $11.00, […] - 2025-02-19 04:30:55
R Squared Ltd Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS)
R Squared Ltd bought a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm bought 1,720 shares of the company’s stock, valued at approximately $26,000. Other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Hong Kong […] - 2025-02-05 06:42:51

iShares Healthcare Innovation UCITS ETF USD (Acc) RCUS holdings

DateNumber of RCUS Shares HeldBase Market Value of RCUS SharesLocal Market Value of RCUS SharesChange in RCUS Shares HeldChange in RCUS Base ValueCurrent Price per RCUS Share HeldPrevious Price per RCUS Share Held
2025-11-11 (Tuesday)90,220USD 1,830,564RCUS holding increased by 74883USD 1,830,5640USD 74,883 USD 20.29 USD 19.46
2025-11-10 (Monday)90,220USD 1,755,681RCUS holding increased by 13533USD 1,755,6810USD 13,533 USD 19.46 USD 19.31
2025-11-07 (Friday)90,220USD 1,742,148RCUS holding decreased by -22555USD 1,742,1480USD -22,555 USD 19.31 USD 19.56
2025-11-06 (Thursday)90,220USD 1,764,703RCUS holding decreased by -17142USD 1,764,7030USD -17,142 USD 19.56 USD 19.75
2025-11-05 (Wednesday)90,220USD 1,781,845RCUS holding decreased by -7218USD 1,781,8450USD -7,218 USD 19.75 USD 19.83
2025-11-04 (Tuesday)90,220USD 1,789,063RCUS holding decreased by -46914USD 1,789,0630USD -46,914 USD 19.83 USD 20.35
2025-11-03 (Monday)90,220USD 1,835,977RCUS holding increased by 56839USD 1,835,9770USD 56,839 USD 20.35 USD 19.72
2025-10-31 (Friday)90,220USD 1,779,138RCUS holding decreased by -42404USD 1,779,1380USD -42,404 USD 19.72 USD 20.19
2025-10-30 (Thursday)90,220USD 1,821,542RCUS holding decreased by -9022USD 1,821,5420USD -9,022 USD 20.19 USD 20.29
2025-10-29 (Wednesday)90,220USD 1,830,564RCUS holding increased by 36990USD 1,830,5640USD 36,990 USD 20.29 USD 19.88
2025-10-28 (Tuesday)90,220USD 1,793,574RCUS holding increased by 115482USD 1,793,5740USD 115,482 USD 19.88 USD 18.6
2025-10-27 (Monday)90,220USD 1,678,092RCUS holding increased by 116384USD 1,678,0920USD 116,384 USD 18.6 USD 17.31
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RCUS by Blackrock for IE00BYZK4776

Show aggregate share trades of RCUS

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-24SELL-76817.31017.445 17.431USD -13,387 11.37 Loss of -4,659 on sale
2025-09-11BUY38911.50012.050 11.995USD 4,666 10.98
2025-07-08SELL-3868.5008.650 8.635USD -3,333 11.09 Profit of 946 on sale
2025-06-24SELL-3948.7508.870 8.858USD -3,490 11.26 Profit of 946 on sale
2025-06-23SELL-3948.6308.750 8.738USD -3,443 11.28 Profit of 1,001 on sale
2025-06-20BUY41,7668.6208.740 8.728USD 364,534 11.30
2025-06-11SELL-2179.08010.155 10.047USD -2,180 11.43 Profit of 299 on sale
2025-05-30SELL-2188.9309.380 9.335USD -2,035 11.54 Profit of 481 on sale
2025-05-21BUY2188.6108.870 8.844USD 1,928 11.70
2025-05-14SELL-1,2968.5408.840 8.810USD -11,418 11.80 Profit of 3,880 on sale
2025-04-30SELL-2168.7508.760 8.759USD -1,892 12.12 Profit of 727 on sale
2025-04-28SELL-2168.2508.460 8.439USD -1,823 12.20 Profit of 813 on sale
2025-04-25SELL-2168.3008.335 8.332USD -1,800 12.24 Profit of 845 on sale
2025-04-11SELL-1,3508.1808.180 8.180USD -11,043 12.61 Profit of 5,987 on sale
2025-04-08SELL-6667.0407.545 7.495USD -4,991 12.79 Profit of 3,528 on sale
2025-04-07SELL-4647.2607.410 7.395USD -3,431 12.86 Profit of 2,534 on sale
2025-03-31SELL-4407.8508.020 8.003USD -3,521 13.11 Profit of 2,248 on sale
2025-03-21SELL-4348.9409.150 9.129USD -3,962 13.47 Profit of 1,885 on sale
2025-03-12SELL-2259.7009.980 9.952USD -2,239 13.90 Profit of 888 on sale
2025-02-28SELL-22410.89010.940 10.935USD -2,449 14.41 Profit of 779 on sale
2025-02-25BUY22410.24010.480 10.456USD 2,342 14.64
2025-02-20SELL-22410.74011.080 11.046USD -2,474 14.85 Profit of 853 on sale
2025-02-19BUY44211.10011.690 11.631USD 5,141 14.92
2025-02-18BUY22110.96012.970 12.769USD 2,822 15.00
2024-12-30SELL-41514.91015.280 15.243USD -6,326 16.11 Profit of 358 on sale
2024-12-06SELL-21217.29018.090 18.010USD -3,818 15.98 Loss of -431 on sale
2024-12-04SELL-21217.10017.433 17.400USD -3,689 15.90 Loss of -319 on sale
2024-12-03SELL-42416.44016.630 16.611USD -7,043 15.88 Loss of -312 on sale
2024-11-21SELL-21914.28014.710 14.667USD -3,212 16.12 Profit of 319 on sale
2024-11-20SELL-23014.62015.010 14.971USD -3,443 16.21 Profit of 284 on sale
2024-11-19SELL-22814.51014.770 14.744USD -3,362 16.31 Profit of 356 on sale
2024-11-18SELL-86014.43015.730 15.600USD -13,416 16.42 Profit of 708 on sale
2024-11-12SELL-21416.77017.760 17.661USD -3,779 16.40 Loss of -270 on sale
2024-11-07SELL-21416.46016.750 16.721USD -3,578 16.28 Loss of -93 on sale
2024-11-05SELL-42815.29015.500 15.479USD -6,625 16.43 Profit of 405 on sale
2024-10-28SELL-21416.66016.970 16.939USD -3,625 17.05 Profit of 24 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RCUS

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19162,0430295,21454.9%
2025-09-1878,9090150,55452.4%
2025-09-17196,741169323,52760.8%
2025-09-1660,86267497,87562.2%
2025-09-1588,2780142,97261.7%
2025-09-12164,0670231,13871.0%
2025-09-11140,8520241,73558.3%
2025-09-10173,8020301,38657.7%
2025-09-0953,6530108,32449.5%
2025-09-08293,1703,700481,54760.9%
2025-09-05215,1660344,51062.5%
2025-09-04300,6200421,10171.4%
2025-09-03193,3100429,46545.0%
2025-09-0292,1320135,34868.1%
2025-08-29120,465158183,30165.7%
2025-08-28196,3270248,28579.1%
2025-08-2778,632375156,63050.2%
2025-08-2657,2650131,37443.6%
2025-08-2573,9950148,21449.9%
2025-08-2285,1490208,00240.9%
2025-08-2194,5900171,77655.1%
2025-08-20111,9560209,82653.4%
2025-08-19183,1940237,87577.0%
2025-08-18101,3810177,55357.1%
2025-08-15141,4060281,57450.2%
2025-08-14143,4850231,87161.9%
2025-08-13132,09799308,11742.9%
2025-08-12211,9390402,86352.6%
2025-08-11204,4730344,92059.3%
2025-08-08100,8049,754263,71338.2%
2025-08-07251,216100493,78750.9%
2025-08-06139,5620238,88358.4%
2025-08-05100,0353,000240,80241.5%
2025-08-0446,25731114,03440.6%
2025-08-0167,2250353,61519.0%
2025-07-3156,8390183,39731.0%
2025-07-3064,8220125,84651.5%
2025-07-2974,5680260,10028.7%
2025-07-28248,8510448,79355.4%
2025-07-25124,2260234,00753.1%
2025-07-2490,9774,124193,86046.9%
2025-07-2359,0150167,26735.3%
2025-07-2235,6402,661128,88427.7%
2025-07-2150,9080139,77236.4%
2025-07-1836,5670114,92731.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.